Please assess the completion status of the following clinical trial:

Trial Title: Tolvaptan for Advanced or Refractory Heart Failure

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Hospital admission for ADHF with volume overload as evidenced by ≥ 2 of the following: Elevated JVP, peripheral edema, ascites, pulmonary rales, congestion on chest X-ray, elevated NT-pro-BNP \> 2000 pg/ml~* Inadequate clinical response indicated by body weight loss \< 1.0 kg/day over 48 hours despite adequate doses of IV loop diuretic (at least 40 mg furosemide daily) and fluid restriction 2 L/24 hours.~* ≥1 of the following over the preceding 48 hours: Potential need for inotropic support to improve urine output, and/or renal insufficiency (estimated glomerular filtration rate \<45 mL/min/1.73 m2)~* Serum sodium ≤134 mmol/L~* ≥18 years-old~Exclusion Criteria:~* Cardiac surgery within 60 days of enrollment~* Planned cardiac mechanical support or transplant; subjects with previously implanted ventricular assist device (VAD) will not be excluded~* Need for intravenous pressor support for symptomatic hypotension~* Biventricular pacemaker placement within the last 60 days~* Hemofiltration or dialysis~* Known cirrhosis~* Supine systolic arterial blood pressure less than 85 mmHg~* Refusal or inability to sign informed consent

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Tolvaptan (Type: EXPERIMENTAL): Tolvaptan 15-60 mg, once daily for 4 days or until hospital discharge
- Standard of care diuretic therapy (Type: ACTIVE_COMPARATOR): Usual standard of care diuretic therapy for patients with acute decompensated heart failure

Based on this trial design, predict the completion outcome and termination type (if applicable).